KLK3 and posterior cortical atrophy: PRISK2 may further reduce unnecessary prostate biopsies, minimise overdiagnosis of indolent PCa, and simultaneously decrease the number of undetected clinically significant PCa diseases, compared to single-PSA-based analysis.